Retrospective Analysis of Dabrafenib +/- Trametinib Compassionate Use

Updated 06/21/2024

Status Completed

Clinical Trial Summary

The purpose of this study is to analyze whether Dabrafenib +/- Trametinib are effective in overall survival, response rates and toxicity in both programs.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT02439411
Study type	Observational
Source	Grupo Español Multidisciplinar de Melanoma
Contact
Status	Completed
Phase
Start date	March 3, 2015
Completion date	September 2016

See also
	Status	Clinical Trial	Phase
	Recruiting	`NCT03132090` - Early Therapy Response Monitoring in Melanoma Patients Using PET/MRI	N/A
	Completed	`NCT01676779` - mRNA Electroporated Autologous Dendritic Cells for Stage III/IV Melanoma	Phase 2
	Terminated	`NCT04577729` - The IRMI-FMT Trial	N/A
	Completed	`NCT00313235` - Combined Modality Treatment for Patients With Stage IV Melanoma	Phase 1/Phase 2
	Recruiting	`NCT03166397` - Adoptive Cell Therapy Following a Non-myeloablative, Lymphodepleting Induction Regimen in Metastatic Melanoma Patients	Phase 2
	Not yet recruiting	`NCT05304546` - Overcoming Primary Resistance to Immunotherapy in Metastatic Melanoma	Phase 2
	Terminated	`NCT00722098` - Comparison Study of Dendritic Cell Vaccine With and Without Cyclophosphamide to Treat Stage IV Melanoma Patients	Phase 2
	Terminated	`NCT03430947` - Vemurafenib Plus Cobimetinib After Radiosurgery in Patients With BRAF-mutant Melanoma Brain Metastases	Phase 2
	Completed	`NCT01189383` - IL15 Dendritic Cell Vaccine for Patients With Resected Stage III (A, B or C) or Stage IV Melanoma	Phase 1/Phase 2
	Completed	`NCT01983124` - Vemurafenib + Fotemustine to Treat Advanced Melanoma Patients With V600BRAF Mutation Recurred While on Vemurafenib	Phase 2
	Completed	`NCT01302496` - Autologous TriMix-DC Therapeutic Vaccine in Combination With Ipilimumab in Patients With Previously Treated Unresectable Stage III or IV Melanoma	Phase 2
	Not yet recruiting	`NCT03493230` - Detection of Plasmatic Cell-free BRAF and NRAS Mutations : a New Tool for Monitoring Patients With Metastatic Malignant Melanoma Treated With Targeted Therapies or Immunotherapy ( MALT )	N/A